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Invasive breast cancer (IBC) evolves through a series of 
increasingly abnormal premalignant stages, over decades 
in most cases [1,2]. Ductal carcinoma in situ (DCIS) is a 
late stage in this evolution and the immediate precursor 
for most IBC. Currently, about 60,000 new cases of DCIS 
are diagnosed in the USA each year [3]. If undetected, at 
least one-third of cases will progress to IBC [4]. About 
200,000 cases of IBC are also diagnosed [3], and nearly all 
evolve from DCIS that was not detected.
Th e incidence of IBC can be dramatically reduced by 
improving our abilities to detect and successfully treat 
DCIS, which will be based on a detailed understanding of 
molecular mechanisms responsible for tumor progres sion. 
Although there is much to learn, recent studies have 
begun to shed light on this important issue [5,6]. Among 
these is an interesting study by Jang and colleagues 
described in a recent issue of Breast Cancer Research, 
which evaluated and compared the frequency of ampli ﬁ -
cation of four oncogenes (HER2, c-MYC, CCND1, and 
FGFR1) in large cohorts of pure DCIS (n = 175), in the 
DCIS component of IBC (n  =  203), and in the corres-
ponding IBC (n  =  427) [1]. Ampliﬁ cation was carefully 
assessed by ﬂ uorescence in situ hybridization on tissue 
microarrays containing triplicate 2  mm cores/sample, 
which is far more tissue than used in most tissue 
microarray studies. Overall, they found reasonable rates 
of ampliﬁ cation for each oncogene in IBC consistent with 
many previous studies [7]. Far fewer studies of DCIS are 
available for comparison.
Th e main focus of the study was to compare ampli-
ﬁ cation between pure DCIS and IBC, hypothesizing that 
diﬀ erences may help identify genes that are important in 
the transition from in situ to invasive disease. In this 
regard, the most notable ﬁ ndings included signiﬁ cantly 
higher rates of HER2 ampliﬁ cation in pure DCIS versus 
IBC (31% vs. 20%; P  =  0.004), which has been shown 
before [8], and signiﬁ cantly lower rates of FGFR1 in pure 
DCIS versus IBC (6% vs. 13%; P = 0.02), which is novel. 
Th ese diﬀ erences were more pronounced in lesions of 
high histological grade (HER2 60% vs. 34%; FGFR1 7% vs. 
16%). Ampliﬁ cation frequencies in intrinsic molecular 
sub types of IBC were also generally consistent with 
previous studies [7]. Jang and colleagues also looked at 
the relationship between ampliﬁ cation and clinical out-
come. In these studies, ampliﬁ cation of FGFR1 was asso-
ciated with signiﬁ cantly reduced disease-free survival in 
patients with IBC (about 10% at 8 years), particularly in 
hormone-receptor-positive patients, although HER2, 
c-MYC, and CCND1 were not prognostic in this cohort.
Th e twofold elevation of FGFR1 ampliﬁ cation in IBC 
versus pure DCIS, and the poor prognosis in IBC, led the 
authors to conclude that activation plays an important 
role in the progression of breast cancer, including, in 
particular, the in situ to invasive transition. Th is is a 
reasonable conclusion in the sense that it is also 
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The incidence of invasive breast cancer (IBC) can 
be dramatically reduced by improving our abilities 
to detect and treat ductal carcinoma in situ (DCIS). 
Progress will be based on a detailed understanding 
of molecular mechanisms responsible for tumor 
progression. An interesting study by Jang and 
colleagues evaluated and compared the frequency 
of amplifi cation of four oncogenes (HER2, c-MYC, 
CCND1 and FGFR1) in large cohorts of pure DCIS, in 
the DCIS component of IBC, and in corresponding 
IBC. Of particular interest, they found a twofold 
increase in FGFR1 amplifi cation in IBC versus pure 
DCIS, and signifi cantly reduced disease-free survival 
in amplifi ed versus unamplifi ed IBC – leading the 
authors to conclude that FGFR1 plays an important 
role in the development and progression of IBC. 
These observations indeed provide hints that FGFR1 
is important in this setting, although the issue is very 
complex and far from resolved.
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con sis tent with previous studies showing that FGFR1 
activation is oncogenic for breast cancer in transgenic 
mice [9], and is associated with increased invasion of 
breast cancer cell lines in vitro [10] and poor prognosis in 
IBC [7,11,12], especially in receptor-positive disease 
[11,12].
Although our understanding of FGFR1 at the molecular 
level is incomplete, important aspects are known about 
its function and the consequences of gene ampliﬁ cation 
[13]. For example, the gene encodes a tyrosine kinase 
receptor that is part of a large family of ﬁ broblast growth 
factors and receptors. In a normal setting, activation of 
FGFR1 can lead to transactivation of mitogen-activated 
protein kinase and AKT, which collectively are essential 
for breast development, including the growth and 
diﬀ erentiation of luminal epithelial cells. However, 
increased FGFR1 activity, such as occurs through gene 
ampliﬁ cation, can result in increased luminal cell proli-
fera tion and, in transgenic mouse models, this hyper-
plasia may eventually evolve into in situ and invasive 
mammary carcinomas.
In humans, the chromosomal region where FGFR1 
resides, 8p11.2, is ampliﬁ ed in signiﬁ cant proportions of 
many types of cancers, including kidney cancer, lung 
cancer, prostate cancer, and leukemias. Th e region is also 
ampliﬁ ed in 10 to 20% of IBC [13]. However, the 8p11.2 
amplicon is large and complex, and FGFR1 is only one of 
several candidate oncogenes within the region [14]  – 
others include LSM1, PPAPDC1B, WHSC1L1, and BAG4, 
which are also important in breast development and cell 
cycle regulation, among other relevant functions. To 
complicate matters more, only about 50% of FGFR1-
ampliﬁ ed tumors appear to overexpress the transcript 
[15].
Th e study by Jang and colleagues provides additional 
evidence of an important role for FGFR1 ampliﬁ cation in 
the progression of IBC [1]. Th e study also provides 
tantalizing hints that FGFR1 may be important in the in 
situ to invasive transition, which is a critical step in the 
progression of a nonlethal to potentially lethal disease – 
and this aspect of the study is entirely novel. Having said 
this, we need to be cautious about drawing conclusions 
regarding gene function and malfunction based on 
correlative studies of this nature alone. For example, the 
main evidence that FGFR1 is important in this study is 
elevated ampliﬁ cation in IBC versus DCIS. By analogous 
reasoning, the elevated ampliﬁ cation of HER2 observed 
in DCIS versus IBC could be taken as evidence for 
suppression of tumor progression, which we know is 
wrong. Determining the molecular function, oncogenic 
potential, and clinical signiﬁ cance of FGFR1 at any stage 
of breast cancer evolution will require many additional 
comprehensive laboratory and clinical studies. Th ese 
studies are particularly worthwhile in the sense that we 
have eﬀ ective drugs to inhibit FGFR1 activity [13]. Jain 
and Turner have summarized recent interesting data in 
terms of the functional biology of the ﬁ broblast growth 
factor receptors and development of inhibitors of these 
molecules, with emphasis on challenges to successfully 
target this pathway in breast cancer [16]. Th ese could 
lead to new strategies for preventing the progression of 
DCIS to IBC, or restoring responsiveness of receptor-
positive IBC to endocrine therapy if activation is 
conﬁ rmed to induce resistance [11,12] – perhaps FGFR1 
will be the next HER2.
Abbreviations
DCIS, ductal carcinoma in situ; FGFR1, fi broblast growth factor receptor 1; 
HER2, human epidermal growth factor receptor 2; IBC, invasive breast cancer.
Competing interests
The authors declare that they have no competing interests.
Published: 14 November 2012
References
1. Jang MH, Kim EJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park 
SY: FGFR1 is amplifi ed during the progression of in situ to invasive breast 
carcinoma. Breast Cancer Res 2012, 14:R115.
2. Allred DC: Biological features of human premalignant breast disease and 
the progression to cancer. In Diseases of the Breast. Edited by Harris JR, 
Lippman ME, Morrow M, Hellman S, Osborne CK. 4th edition. New York: 
Lippincott Williams and Wilkins; 2009:323-334.
3. American Cancer Society: Breast Cancer Facts and Figures; Atlanta, GA: 
American Cancer Society Inc.; 2011–2012.
4. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, 
Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers 
G, Zon R: National Institutes of Health State-of-the-Science Conference 
statement: Diagnosis and Management of Ductal Carcinoma In Situ 
September 22–24, 2009. J Natl Cancer Inst 2010, 102:161-169.
5. Polyak K: Breast cancer: origins and evolution. J Clin Invest 2007, 
117:3155-3163.
6. Lee S, Stewart S, Nagtegaal I, Luo J, Wu Y, Colditz G, Medina D, Allred DC: 
Diff erentially expressed genes regulating the progression of ductal 
carcinoma in situ to invasive breast cancer. Cancer Res 2012, 72:4574-4586.
7. Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, 
Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauff ret E, 
Jacquemier J, Birnbaum D, Chaff anet M: Frequency, prognostic impact, and 
subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 
amplifi cations in breast cancers. BMC Cancer 2006, 6:245.
8. Latta EK, Tjan S, Parkes RK, O’Malley FP: The role of HER2/neu 
overexpression/amplifi cation in the progression of ductal carcinoma in 
situ to invasive carcinoma of the breast. Mod Pathol 2002, 15:1318-1325.
9. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM: 
Inducible dimerization of FGFR1: development of a mouse model to 
analyze progressive transformation of the mammary gland. J Cell Biol 2002, 
157:703-714.
10. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM: Pleiotropic eff ects of 
FGFR1 on cell proliferation, survival, and migration in a 3D mammary 
epithelial cell model. J Cell Biol 2005, 171:663-673.
11. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, 
Ellis IO, Reis-Filho JS: FGFR1 amplifi cation in breast carcinomas: a 
chromogenic in situ hybridisation analysis. Breast Cancer Res 2007, 9:R23.
12. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan 
R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, 
Ashworth A: FGFR1 amplifi cation drives endocrine therapy resistance and 
is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094.
13. Schwertfeger KL: Fibroblast growth factors in development and cancer: 
insights from the mammary and prostate glands. Curr Drug Targets 2009, 
10:632-644.
14. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, Lasorsa L, 
Letessier A, Ginestier C, Monville F, Esteyriès S, Adélaïde J, Esterni B, Henry C, 
Gru and Allred Breast Cancer Research 2012, 14:116 
http://breast-cancer-research.com/content/14/6/116
Page 2 of 3
Ethier SP, Bibeau F, Mozziconacci MJ, Charafe-Jauff ret E, Jacquemier J,Bertucci 
F, Birnbaum D, Theillet C, Chaff anet M: Comprehensive profi ling of 8p11-12 
amplifi cation in breast cancer. Mol Cancer Res 2005, 3:655-667.
15. Gru AA, Salavaggione AL, Hoog J, Snyder J, Tao Y, Ellis M, Allred DC: 
Amplifi cation of FGFR1 gene and its relationship with gene expression 
and clinical signifi cance in breast cancer. Modern Pathol 2010, 48a:206.
16. Jain VK, Turner NC: Challenges and opportunities in the targeting of 
fi broblast growth factor receptors in breast cancer. Breast Cancer Res 2012, 
14:208.
doi:10.1186/bcr3340
Cite this article as: Gru AA, Allred DC: FGFR1 amplifi cation and the 
progression of non-invasive to invasive breast cancer. Breast Cancer Research 
2012, 14:116.
Gru and Allred Breast Cancer Research 2012, 14:116 
http://breast-cancer-research.com/content/14/6/116
Page 3 of 3
